Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, cytarabine, and idarubicin,
work in different ways to stop cancer cells from dividing so they stop growing or die.
Combining more than one drug may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide
when given together with cytarabine and idarubicin in treating patients with acute myeloid
leukemia.